Ainos, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021, compared with FY2020. This is an annual report, not a standalone fourth-quarter report. Amounts below are in U.S. dollars unless stated otherwise.
Business context
Ainos develops point-of-care testing (POCT) devices and therapeutics, including low-dose oral interferon. In 2021, it shifted its emphasis toward medical devices and acquired intellectual property from its controlling shareholder, Ainos KY. Its first commercial product was an Ainos-branded COVID-19 antigen rapid test kit sold in Taiwan under TFDA emergency use authorization (EUA), manufactured by affiliated company TCNT. The company reported 34 full-time and one part-time employee at year-end.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $594,563 | $16,563 |
| Cost of revenue | $184,181 | $11,277 |
| Gross profit / margin | $410,382 / 69% | $5,286 / 32% |
| Research and development | $1,920,645 | $389 |
| Selling, general and administrative | $2,357,163 | $1,445,332 |
| Operating loss | $(3,867,426) | $(1,440,435) |
| Net loss | $(3,888,661) | $(1,450,623) |
| Net loss per share, basic and diluted | $(0.03) | $(0.04) |
| Cash used in operations | $(1,249,977) | $(499,551) |
| Cash and cash equivalents, year-end | $1,751,499 | $22,245 |
Revenue rose 3,490%, primarily from antigen test-kit sales beginning in June; substantially all FY2021 operating revenue came from those kits. The company separately reported $568,164 of kit revenue. Despite the improved gross margin, operating expenses grew substantially and the net loss widened by 168%. R&D costs included approximately $1.265 million of acquired-IP amortization; total depreciation and amortization was $2.044 million.
At year-end, current assets were $2.218 million and current liabilities were $30.595 million, implying negative working capital of approximately $28.377 million. Total assets were $40.822 million, including $37.329 million of net intangible assets; total liabilities were $30.625 million. The balance sheet includes a $26 million related-party payable for assets acquired from Ainos KY; the purchase closed and was settled with a note in January 2022. The filing reports $3.590 million of convertible and other notes payable at year-end. Operating cash outflow was partly funded by $3.154 million of net financing cash inflow, principally related-party convertible notes.
Material changes and transactions
- On April 15, 2021, Ainos issued Ainos KY 100 million shares, valued at $20 million, in exchange for intellectual property. Ainos KY became the controlling shareholder; its reported voting power was 77.64% at year-end.
- In November 2021, Ainos agreed to acquire additional IP, equipment and related assets from Ainos KY for $26 million. The January 2022 closing was funded with a non-interest-bearing convertible note due January 2027, convertible at 80% of the price in a qualifying U.S.-listed public offering.
- Ainos reported $3 million of 2021 working-capital advances from Ainos KY through convertible notes, generally bearing 1.85% interest and convertible at $0.20 per share. Certain maturities were subsequently extended to February 2023.
- Common shares outstanding increased from 42.1 million to 144.4 million, including the 100 million shares issued for IP. The filing also reports 17.2 million shares reserved for convertible-debt conversion, plus other reserved shares.
- The company entered a five-year product-development agreement with TCNT, under which Ainos funds development and TCNT provides personnel and facilities; the parties jointly own resulting research IP. Ainos reported $205,883 of development expense in 2021.
Outlook, risks and unusual items
Management’s stated 2022 priorities were POCT commercialization and regulatory submissions, alongside planned clinical work on the CICCT antiviral program. At the filing date, management expected a U.S. FDA EUA submission for COVID-19 tests in mid-2022; Taiwan trials and applications for Ainos Flora in 2022; and later development of Ainos Pen, CHS430, VELDONA and synthetic RNA programs. These were plans and expectations, not assured outcomes. The filing says the nucleic-acid test was under TFDA EUA review.
The auditor and management both cited substantial doubt about Ainos’s ability to continue as a going concern, given recurring losses, negative working capital and operating cash outflows. Management expected business revenue and potential outside financial support to fund operations for the next 12 months, but said additional capital was needed and could not be assured. The auditor’s opinion states the financial statements fairly present the company’s position under U.S. GAAP, while highlighting the going-concern uncertainty.
Key risks include dependence on a small number of COVID-19 test-kit customers and Taiwan market demand; regulatory approval or EUA renewal; reliance on affiliated TCNT for development and manufacturing; the need for external financing; product-development and clinical-trial uncertainty; and related-party governance and dilution. The filing states there were no current legal proceedings and no off-balance-sheet arrangements. It also reports no dividends. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to audit internal controls.
The filing contains an apparent regulatory-status inconsistency: one section says the company received FDA EUA for the antigen kit on November 17, 2020, while other sections describe Taiwan EUA as the authorization then in place and anticipate a U.S. FDA submission in mid-2022. The filing text does not reconcile these statements.
Important facts for investors to verify
- Confirm current cash runway, financing availability, and the status and terms of the $26 million Ainos KY note and other related-party obligations.
- Reconcile the stated FDA EUA history with the company’s planned U.S. submissions, and verify current TFDA and FDA authorization status for each product.
- Assess actual kit sales, customer concentration, the 60% profit-share arrangement, and whether demand can expand beyond Taiwan.
- Review the valuation, ownership and commercial rights associated with IP acquired from controlling shareholder Ainos KY, as well as the potential dilution from convertible notes and share reserves.
- Verify filing compliance: the 10-K cover page marks “No” for having filed all required Exchange Act reports during the preceding 12 months.